8 Amendments of Tomáš ZDECHOVSKÝ related to 2014/2102(DEC)
Amendment 2 #
Proposal for a decision 1
Paragraph 1
Paragraph 1
1. Grants the Executive Director of the European Medicines Agency discharge in respect of the implementation of the Agency’s budget for the financial year 2013 / Postpones its decision on granting the Executive Director of the European Medicines Agency discharge in respect of the implementation of the Agency’s budget for the financial year 2013;
Amendment 4 #
Proposal for a decision 2
Paragraph 2
Paragraph 2
2. Approves the closure of the accounts of the European Medicines Agency for the financial year 2013 / Postpones the closure of the accounts of the European Medicines Agency for the financial year 2013;
Amendment 6 #
Motion for a resolution
Paragraph 2 – indent 3
Paragraph 2 – indent 3
– in order to improve its communication with Union citizens, the Agency has recently implemented several initiatives such as publication of strategic documents including summaries for the public, meeting highlights, newsletters or annual reports; notes furthermore in this regard the development of IT communication tools such as ‘Public health communication’ which provides the public with key information on medicines, mainly on their safety; in this regard encourages the Agency to set the pharmacovigilance public hearings;
Amendment 7 #
Motion for a resolution
Paragraph 3 a (new)
Paragraph 3 a (new)
3 a. Notes that 83% of Agency´s budget comes from the industry fees, representing gradual increase; requires complete transparency about this aspect of budget to avoid any risks for consumers´ rights or Agency´s reputation;
Amendment 8 #
Motion for a resolution
Paragraph 6 a (new)
Paragraph 6 a (new)
6 a. Notes that the Agency faced some controversy regarding several cases of recruitment procedures in the past; calls on the Agency to always ensure complete transparency and clarification with regard to the recruitment procedures;
Amendment 10 #
Motion for a resolution
Paragraph 7
Paragraph 7
7. Acknowledges from the Agency that the transparency criteria for partner, patient, healthcare and consumer organisations has been revised during 2014 in order to increase the transparency of funding; notes the adoption of the document with detailed criteria regarding the evaluation of financial information from patients, consumers and healthcare professionals organisations; notes furthermore that this document is used for assessing the organisations’ eligibility to participate in the dialogue with the Agency; recalls that the document also states that the organisations have to declare any conflict of interests at the start of the meetings through which the dialogue is commenced; further calls on the Agency to introduce a list of the patients´ organizations it is working with and to place it on its website, linking it to the funding sources of these organizations in order to enhance transparency;
Amendment 12 #
Motion for a resolution
Paragraph 8
Paragraph 8
8. Notes that the Agency's Management Board has endorsed thea revised the policy on the handling of declarations of interests of members of scientific committees and experts; regrets that the main loopholes, such as distinction between direct and indirect conflicts of interest, prevail, while the Agency takes into account mainly only direct conflict of interest; notes that the electronic declaration of interests form and the procedural guidance were to be finalised during 2014; calls on the Agency to inform the discharge authority on the outcomes as soon as they are available;
Amendment 16 #
Motion for a resolution
Paragraph 8 d (new)
Paragraph 8 d (new)
8 d. Regrets that the policies on proactive publication of clinical trial data recently adopted by the Agency go against the transparent provisions of the Clinical Trials Regulation endorsed by the European Parliament by allowing companies to redact data based on potential jeopardy of commercial interests; calls on the Agency to report to the discharge Authority on this issue;